

Hugh S Griffith Chief Executive Officer T: +44 (0) 131 248 3660 E: info@nucanabiomed.com W: www.nucanabiomed.com

Edinburgh, U.K., 17 February 2014

## Important Results of NuCana's lead ProTide published in prominent scientific journal.

NuCana (www.nucanabiomed.com) is pleased to announce that a major article on the company's lead anti-cancer agent, Acelarin<sup>™</sup>, has been published in the prominent specialised journal, the Journal of Medicinal Chemistry (Slusarczyk et al., 2014). The scientific article presents the results of detailed studies on the selection and non-clinical analyses of Acelarin.

Acelarin belongs to a new class of agents, ProTides, specifically designed to overcome the key cancer resistance mechanisms that limit the efficacy of many chemotherapeutic drugs currently prescribed.

Chris McGuigan, Professor of Pharmacy at Cardiff University and inventor of the ProTide technology stated "the publication of this paper in a much-respected journal is the culmination of many years of work on ProTides and it is exciting to see Acelarin making a difference in the lives of cancer patients."

NuCana has built the ProTide platform to develop a portfolio of specialised medicines, designed to overcome drug resistances in a broad range of cancers. Acelarin is about to complete the Phase I clinical study of patients with advanced progressive cancers and is already showing encouraging signals of efficacy. NuCana plans to have three further ProTides in the clinic within the next 12-18 months.

## About NuCana

NuCana is a clinical stage biopharmaceutical company developing and commercialising a range of exciting, new anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.

For further information, please visit www.nucana.com

## About ProTides

The distinctive feature of a ProTide is the ability to bypass the key cancer cell resistance pathways and generate high levels of the active agent inside the cancer cells. The fundamental aspect of the ProTide technology platform is the addition of a phosphoramidate moiety onto a nucleoside analogue scaffold. As such, it is applicable to all nucleoside analogues. NuCana's vision is to replace all commonly used nucleoside analogue-based treatments with more active and safer ProTides.